DrugPatentWatch Database Preview
Details for Patent: 6,573,293
Which drugs does patent 6,573,293 protect, and when does it expire?
Patent 6,573,293 protects SUTENT and is included in one NDA.
Protection for SUTENT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty-two patent family members in forty-one countries.
Summary for Patent: 6,573,293
| Title: | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| Abstract: | The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer. |
| Inventor(s): | Tang; Peng Cho (Moraga, CA), Miller; Todd A. (Bend, OR), Li; Xiaoyuan (Los Altos, CA), Sun; Li (Foster City, CA), Wei; Chung Chen (Foster City, CA), Shirazian; Shahrzad (Corte Madera, CA), Liang; Congxin (Sunnyvale, CA), Vojkovsky; Tomas (San Francisco, CA), Nematalla; Asaad S. (Concord, CA), Hawley; Michael (Kalamazoo, MI) |
| Assignee: | Sugen, Inc. (South San Francisco, CA) Pharmacia & Upjohn Co. (Kalamazoo, MI) |
| Application Number: | 09/783,264 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,573,293 |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for Patent 6,573,293 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 6,573,293
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-001 | Jan 26, 2006 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||||
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-002 | Jan 26, 2006 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||||
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-004 | Mar 31, 2009 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||||
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-003 | Jan 26, 2006 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
International Family Members for US Patent 6,573,293
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 034118 | ➤ Sign Up | |||
| Austria | 369359 | ➤ Sign Up | |||
| Australia | 2001239770 | ➤ Sign Up | |||
| Australia | 3977001 | ➤ Sign Up | |||
| Bulgaria | 107078 | ➤ Sign Up | |||
| Bulgaria | 65764 | ➤ Sign Up | |||
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
